目次

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hypoparathyroidism - Overview
Hypoparathyroidism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hypoparathyroidism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hypoparathyroidism - Companies Involved in Therapeutics Development
Aerami Therapeutics Inc
Aeterna Zentaris Inc
Amolyt Pharma
Ascendis Pharma AS
BridgeBio Pharma Inc
Eli Lilly and Co
Entera Bio Ltd
Extend Biosciences Inc
GC Biopharma Corp
MBX Biosciences Inc
ProLynx LLC
Rani Therapeutics LLC
Hypoparathyroidism - Drug Profiles
Aerami-701 - Drug Profile
Product Description
Mechanism Of Action
AEZS-150 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AZP-3601 - Drug Profile
Product Description
Mechanism Of Action
History of Events
encaleret - Drug Profile
Product Description
Mechanism Of Action
History of Events
EXT-608 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LY-6272K - Drug Profile
Product Description
Mechanism Of Action
MBX-2109 - Drug Profile
Product Description
Mechanism Of Action
History of Events
palopegteriparatide - Drug Profile
Product Description
Mechanism Of Action
History of Events
PLX-134 - Drug Profile
Product Description
Mechanism Of Action
History of Events
RT-110 - Drug Profile
Product Description
Mechanism Of Action
Stem cell Therapy - Drug Profile
Product Description
Mechanism Of Action
teriparatide - Drug Profile
Product Description
Mechanism Of Action
History of Events
Hypoparathyroidism - Dormant Projects
Hypoparathyroidism - Discontinued Products
Hypoparathyroidism - Product Development Milestones
Featured News & Press Releases
Sep 12, 2022: New long-term data in adult patients with hypoparathyroidism treated with Ascendis Pharma's TransCon PTH through Week 110 in the PaTH forward trial presented at ASBMR 2022
Aug 31, 2022: Ascendis pharma submits TransCon PTH new drug application to the U.S. FDA for adult patients with hypoparathyroidism
Jul 26, 2022: MBX Biosciences receives Orphan Drug Designation for lead candidate MBX 2109 for the treatment of hypoparathyroidism
Jun 14, 2022: Ascendis Pharma announces two oral presentations highlighting the potential for TransCon PTH to be a replacement therapy for adult hypoparathyroidism at ENDO 2022
Jun 14, 2022: BridgeBio Pharma to present phase 2b data and pivotal phase 3 study design of encaleret in autosomal dominant hypocalcemia type 1 (ADH1) at the Endocrine Society (ENDO) 2022 Annual Conference
Jun 13, 2022: BridgeBio Pharma shares positive phase 2b data and announces pivotal study design for phase 3 trial of encaleret in autosomal dominant hypocalcemia type 1 (ADH1)
May 01, 2022: Ascendis Pharma to present TransCon PTH new endocrinology results at Medical Meetings in May
Mar 13, 2022: Ascendis Pharma announces phase 3 PaTHway Trial of TransCon PTH in adults with hypoparathyroidism met primary and all key secondary endpoints
Mar 02, 2022: Aeterna Zentaris announces notice of allowance for U.S. patent covering AEZS-150 for the potential treatment of chronic hypoparathyroidism
Nov 18, 2021: Ascendis Pharma announces top-line results from Week 84 of its phase 2 PaTH forward trial demonstrating that TransCon PTH provided durable benefit and was well-tolerated in adults with hypoparathyroidism
Oct 01, 2021: BridgeBio Pharma announces updated phase 2b data for Encaleret in autosomal dominant hypocalcemia type 1 (ADH1) demonstrating blood and urine calcium normalization in trial participants
Sep 22, 2021: Ascendis Pharma announces mean bone mineral density (BMD) data from phase 2 PaTH Forward Trial demonstrating continued normalization and stabilization of BMD Z-scores between 26 and 58 weeks
Jul 06, 2021: Ascendis Pharma announces target enrollment achieved in the Phase 3 PaTHway trial of TransCon PTH (palopegteriparatide) in adults with hypoparathyroidism (HP) and provides a comprehensive global clinical program update
Jun 03, 2021: The first hormone replacement therapy for hypoparathyroidism in China obtains IND approval for Phase III clinical trial
Jun 01, 2021: BridgeBio Pharma receives FDA Fast Track designation for encaleret for the treatment of autosomal dominant hypocalcemia type 1
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Hypoparathyroidism, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Hypoparathyroidism - Pipeline by Aerami Therapeutics Inc, 2022
Hypoparathyroidism - Pipeline by Aeterna Zentaris Inc, 2022
Hypoparathyroidism - Pipeline by Amolyt Pharma, 2022
Hypoparathyroidism - Pipeline by Ascendis Pharma AS, 2022
Hypoparathyroidism - Pipeline by BridgeBio Pharma Inc, 2022
Hypoparathyroidism - Pipeline by Eli Lilly and Co, 2022
Hypoparathyroidism - Pipeline by Entera Bio Ltd, 2022
Hypoparathyroidism - Pipeline by Extend Biosciences Inc, 2022
Hypoparathyroidism - Pipeline by GC Biopharma Corp, 2022
Hypoparathyroidism - Pipeline by MBX Biosciences Inc, 2022
Hypoparathyroidism - Pipeline by ProLynx LLC, 2022
Hypoparathyroidism - Pipeline by Rani Therapeutics LLC, 2022
Hypoparathyroidism - Dormant Projects, 2022
Hypoparathyroidism - Discontinued Products, 2022

List of Figures
Number of Products under Development for Hypoparathyroidism, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022